Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Gut microbiome may modulate the efficacy of CAR-T cell cancer immunotherapy

Gut microbiome may modulate the efficacy of CAR-T cell cancer immunotherapy

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Understanding the relationship between gut microbiome and CAR T-cell therapy response

The mechanism behind fruit fly germ cells forming ring canals

The mechanism behind fruit fly germ cells forming ring canals

Herpesvirus infection boosts host cellular immunity: Study

Herpesvirus infection boosts host cellular immunity: Study

Whole genome sequencing might help better assess tumor evolution

Whole genome sequencing might help better assess tumor evolution

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

Analyzing the immune microenvironment around Hodgkin lymphoma tumors

Analyzing the immune microenvironment around Hodgkin lymphoma tumors

Protein that facilitates cancer-causing viruses dodge the immune system

Protein that facilitates cancer-causing viruses dodge the immune system

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

Novel blood biomarker predicts a favorable response to CART cell therapy

Novel blood biomarker predicts a favorable response to CART cell therapy

Major development in re-treatment with CAR T therapy

Major development in re-treatment with CAR T therapy

Resistance against Epstein-Barr virus from experimental monoclonal antibodies

Resistance against Epstein-Barr virus from experimental monoclonal antibodies

Simple blood test helps identify patients developing neurotoxic side effects

Simple blood test helps identify patients developing neurotoxic side effects

Researchers find immune-effective ways to destroy cancer cells

Researchers find immune-effective ways to destroy cancer cells

Scientists discover proteins that may improve CAR-T cell therapy for solid tumor model

Scientists discover proteins that may improve CAR-T cell therapy for solid tumor model

Researchers discover a new interferon-gamma receptor signaling pathway

Researchers discover a new interferon-gamma receptor signaling pathway

Study shows new potential target for CAR T cells to inhibit solid tumors

Study shows new potential target for CAR T cells to inhibit solid tumors

Gene expression signatures in lymph node cells play an active role in lymphoma development

Gene expression signatures in lymph node cells play an active role in lymphoma development

CAR-T cell treatment via implantable biotechnology more effective in combating cancer

CAR-T cell treatment via implantable biotechnology more effective in combating cancer

Study uncovers genomic drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma

Study uncovers genomic drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.